Immunovant, Inc.

By person

23 insiders · 289 transactions

17.2×

Eric Venker holds 17.2 times base salary in stock. $11.00M of shares against $636.62K in salary for 2026.

Salary from the company's own proxy. The shares are what Eric Venker last reported holding, valued at $43.27, the price Common Stock was last bought or sold at on the open market here, on 28 Aug 2026.

Insider

Role

Bought

Sold

Net

Holding

Of company

Worth

Change

Roivant Sciences Ltd. entity

Director

$774.94M (6)

—

+$774.94M

113,317,007

54.86%

$4.90B

+23,264%

Salzmann Peter

Chief Executive Officer

—

$12.74M (41)

−$12.74M

1,178,191

0.5704%

$50.98M

—

WONG RODERICK

Chief Executive Officer

$9.27M (23)

—

+$9.27M

902,498

0.4369%

$39.05M

—

Fromkin Andrew J.

Director

$43.45K (1)

$8.60M (9) scheduled

−$8.56M

74,382

0.0360%

$3.22M

—

Barnett Eva Renee

Chief Financial Officer

—

$3.07M (33)

−$3.07M

396,774

0.1921%

$17.17M

—

Stout Jay S

Chief Technology Officer

—

$2.86M (23)

−$2.86M

205,341

0.0994%

$8.89M

—

Butchko Julia G.

Chief Development Officer

$190.85K (1)

$2.72M (30)

−$2.53M

440,959

0.2135%

$19.08M

—

Macias William L.

Chief Medical Officer

—

$2.28M (35)

−$2.28M

357,353

0.1730%

$15.46M

—

Levine Mark S.

Chief Legal Officer

—

$2.10M (23)

−$2.10M

319,228

0.1546%

$13.81M

—

Gloria Melanie

Chief Operating Officer

—

$1.60M (14)

−$1.60M

219,301

0.1062%

$9.49M

—

Girao Tiago

Chief Financial Officer

—

$1.41M (3)

−$1.41M

240,798

0.1166%

$10.42M

—

Van Tuyl Christopher

Chief Legal Officer

—

$1.31M (9) scheduled

−$1.31M

179,391

0.0868%

$7.76M

—

Pande Atul

Director

$123.90K (2)

$1.14M (9) scheduled

−$1.01M

136,731

0.0662%

$5.92M

—

Geffner Michael

Chief Medical Officer

—

$978.32K (12)

−$978.32K

217,958

0.1055%

$9.43M

+118.0%

Venker Eric

Chief Executive Officer

—

$461.83K (3)

−$461.83K

254,280

0.1231%

$11.00M

—

MIGAUSKY GEORGE V

Director

$53.55K (1)

$504.57K (3) scheduled

−$451.02K

137,251

0.0664%

$5.94M

+586.3%

Hughes Douglas J.

Director

$150.36K (1)

$503.49K (3) scheduled

−$353.14K

134,653

0.0652%

$5.83M

—

Torti Frank

Director

$116.20K (1)

—

+$116.20K

1,009,228

0.4886%

$43.67M

—

Susman Robert Graham

Director

—

$67.98K (1) scheduled

−$67.98K

36,394

0.0176%

$1.57M

—

Jain Rita

Chief Medical Officer

—

129,365

0.0626%

$5.60M

—

Elliott Michael James

Chief Scientific Officer

—

97,600

0.0473%

$4.22M

—

Connealy Pamela Ann

Chief Financial Officer

—

46,200

0.0224%

$2.00M

—

Bauer Jake

Director

—

38,896

0.0188%

$1.68M

—

Individual transactions

Insider

Date

Role

Action

Price

Amount

Roivant Sciences Ltd.

12 Dec 2025

Director

Buy

16,666,666

$21.00

$350.00M

Roivant Sciences Ltd.

13 Jan 2025

Director

Buy

16,845,010

$20.00

$336.90M

Roivant Sciences Ltd.

2 Oct 2023

Director

Buy

1,526,316

$38.00

$58.00M

Roivant Sciences Ltd.

6 Oct 2022

10% owner

Buy

416,667

$6.00

$2.50M

Pande Atul

30 Sep 2022

Director

Buy indirect

15,000

$5.60

$84.00K

Torti Frank

29 Sep 2022

Director

Buy

20,000

$5.81

$116.20K

Showing 250 of 289 transactions. The figures above use every one of them.

By person

Individual transactions

What was left out